1887

Chapter 31 : Regulatory T Cell (Treg) Assays: Repertoire, Functions, and Clinical Importance of Human Treg

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Regulatory T Cell (Treg) Assays: Repertoire, Functions, and Clinical Importance of Human Treg, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH31-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH31-2.gif

Abstract:

Regulatory T cells (Treg) are a small subset (<5%) of circulating CD4 T cells. Due to their ability to suppress functions of other lymphocytes, Treg are responsible for maintaining immune responses in balance. This system of immune checks and balances exists to protect us from autoimmune diseases, prevent tissue damage resulting from intense inflammatory responses induced by infectious or non-infectious injuries and to contain chronic inflammatory reactions that might promote tumor development (1). Treg seem to be capable of fulfilling all these functions, largely due to their plasticity, which allows them to readily adjust to conditions in the local microenvironment (2). Viewed in this context, Treg can be considered as a protective mechanism designed to limit inflammatory tissue damage, but also as a potentially dangerous suppressor of immune responses that benefit the host. For example, in chronic viral infections such as HIV-1 infections, Treg could either suppress excessive immune activation, thus benefiting the host, or limit antiviral immunity needed by the host to contain the infection. Today, the role of Treg in HIV-1 remains highly controversial (3). In cancer, Treg are emerging both as contributors to cancer progression, because of their ability to block anti-tumor immune responses, and also as inhibitors of cancer progression via their ability to suppress cancer-promoting inflammation (4). It is unclear whether the anti-inflammatory activity of Treg or their suppression of antitumor immunity contributes to disease outcome, and the mechanisms responsible for regulation of Treg functions remain unknown. Factors that govern Treg behavior are being intensely investigated in various human diseases. An excess of Treg (e.g., in some cancers) or their numerical or functional deficiency (e.g., in autoimmune diseases) is associated with clinical symptoms and may predict outcome. For these reasons, measurements of Treg frequency and function in the circulation, and especially in tissues, are of great importance.

Citation: Whiteside T. 2016. Regulatory T Cell (Treg) Assays: Repertoire, Functions, and Clinical Importance of Human Treg, p 296-299. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch31
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818722.ch31
1. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. 2010. Regulatory T cells in cancer. Adv Cancer Res. 107:57117.[CrossRef].[PubMed]
2. Addey C, White M, Dou L, Coe D, Dyson J, Chai JG. 2011. Functional plasticity of antigen-specific regulatory T cells in context of tumor. J Immunol. 186:45574564.[CrossRef].[PubMed]
3. Angin M, Sharma S, King M, Murooka TT, Ghebremichael M, Mempel TR, Walker BD, Bhasin MK, Addo MM. 2014. HIV-1 infection impairs regulatory T cell suppressive capacity on a per-cell basis. J Infect Dis 210:899903.[CrossRef].[PubMed]
4. Whiteside TL. 2012. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327334.[CrossRef].[PubMed]
5. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. 2012. The prognostic value of FOXP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18:30223029.[CrossRef].[PubMed]
6. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF. 2013. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 14:307308.[CrossRef].[PubMed]
7. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. 2007. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:88658873.[CrossRef].[PubMed]
8. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann T, Johnson J, Lang S, Whiteside TL. 2012. Phenotypic and functional characteristics of ATP-hydrolysing CD4+CD39+FOXP3+ and CD4+CD39+FOXP3neg T cell subsets in patients with cancer. Eur J Immunol 42:18761885.[CrossRef].[PubMed]
9. Whiteside TL. 2014. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 14:14111425.[CrossRef]
10. Whiteside TL, Schuler P, Schilling B. 2012. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12:13831397.[CrossRef]
11. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rötzschke O, Falk K. 2007. Expression of ectonucleotidase CD39 by FoxP3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:12251232.[CrossRef].[PubMed]
12. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:12571265.[CrossRef].[PubMed]
13. Schuler PJ, Macatangay BJ, Saze Z, Jackson EK, Riddler SA, Buchanan WG, Hilldorfer BB, Mellors JW, Whiteside TL, Rinaldo CR. 2013. CD4+CD73+ T cells are associated with lower T cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 27:15451555.[CrossRef].[PubMed]
14. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE, Rustin MH, Taams LS, Beverley PC, Macallan DC, Akbar AN. 2006. Human CD4+ CD25hi FOXP3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116:24232433.[CrossRef].[PubMed]
15. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. 2010. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285:71767186.[CrossRef].[PubMed]
16. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. 2013. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109:26292635.[CrossRef].[PubMed]
17. Elkord E, Alcantar-Orozco EM, Dovedi SJ. 2010. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 10:15731586.[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Phenotypic characteristics of human nTreg, iTreg, and CD4+T conventional

Citation: Whiteside T. 2016. Regulatory T Cell (Treg) Assays: Repertoire, Functions, and Clinical Importance of Human Treg, p 296-299. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch31
Generic image for table
TABLE 2

Functional assays for human nTreg and iTreg

Citation: Whiteside T. 2016. Regulatory T Cell (Treg) Assays: Repertoire, Functions, and Clinical Importance of Human Treg, p 296-299. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch31

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error